Zepbound Cost in 2026: List Price, LillyDirect Self-Pay & Out-of-Pocket Guide

Ask “what is the cost of Zepbound?” and you quickly find there is no single answer. Instead there is a structure of prices that depends on your dose, how you buy the medicine, whether you have insurance, and which manufacturer program you use. This guide brings those pieces together for 2026: the list price, Eli Lilly’s LillyDirect self-pay vial tiers by dose, out-of-pocket costs with commercial insurance, what you pay without insurance, the savings card and its rules, coverage barriers like prior authorization and employer exclusions, Medicare and Medicaid notes, and practical ways to lower the bill.

Every figure here is an estimate drawn from recent manufacturer pages and reporting as of early 2026, meant to explain the pricing landscape rather than to quote a guaranteed number. Prices in this category move often, so always verify the current price for your own dose and situation directly at the official source — LillyDirect, Lilly’s Zepbound savings page, and your pharmacy. This article is general consumer information, not medical or financial advice.

Why there is no single “Zepbound price”

Zepbound is Eli Lilly’s brand of tirzepatide, a once-weekly injectable prescription medicine for chronic weight management and, in some adults with obesity, moderate-to-severe obstructive sleep apnea (OSA). Because it is prescription-only, a clinician evaluates and prescribes it, and every pricing route below still requires a valid prescription — you cannot buy it off the shelf. Dosing is prescriber-directed and adjusted only under medical supervision; this article does not provide dosing instructions.

The price you actually see is shaped by three things at once. First, your dose: Zepbound comes in several strengths, and the manufacturer’s self-pay vials are priced by dose, so a higher maintenance strength can cost more than a starter strength. Second, how you buy it: a traditional pharmacy pen versus Lilly’s direct self-pay vials are two different price worlds. Third, which program or discount applies: insurance coverage, a manufacturer savings card, or straight cash self-pay each produce a different number. Change any one of those and the price changes — which is why a friend’s cost may look nothing like yours.

One clarification that matters for cost: Zepbound and Mounjaro contain the same active ingredient, tirzepatide, but they are different brands with different FDA-approved uses. Zepbound is approved for weight management and OSA; Mounjaro is approved for type 2 diabetes. That distinction drives a lot of insurance coverage differences, as explained below. Zepbound received FDA approval for chronic weight management in November 2023, and in late 2024 it also became the first medication FDA-approved to treat moderate-to-severe OSA in adults with obesity.

The Zepbound list price and retail cost

Understanding the baseline is the first step in estimating your personal out-of-pocket cost.

List price. Bought the traditional way — a pharmacy pen with no insurance and no discount — Zepbound is expensive. Reporting and Lilly’s own pages have put the list price for a month’s supply of the single-dose pens in the neighborhood of roughly $1,000 or more as of early 2026. Historically this list figure has been the same across doses for the pens, and it has been adjusted over time, so confirm the current number on Lilly’s official pricing pages before budgeting.

Retail pharmacy cost. Without insurance and without any discount, the cash price for the pens at retail pharmacies typically runs in the four-figure range per month. Prices vary by pharmacy, and independent pharmacies sometimes differ from chains. That said, most cash-paying patients today use Lilly’s lower-cost self-pay vials (described next) rather than buying pens at full retail.

Annual cost at full price. At the pens’ list price, a year of Zepbound would run well into five figures — a full-retail path can add up to well over $12,000 across a year. For a medication that current evidence suggests needs to be taken long-term to maintain results, that represents a substantial ongoing commitment, which is exactly why the savings pathways below matter. This undiscounted retail figure is the ceiling, not the number most people actually pay once self-pay vials and savings are considered.

How the LillyDirect self-pay vial tiers work

The most distinctive part of Zepbound’s pricing is Eli Lilly’s direct self-pay program, which sells single-dose vials (and, in 2026 reporting, single-patient-use pens) through LillyDirect at prices set by dose. This route is aimed largely at people whose insurance does not cover Zepbound. Recent reporting from outlets such as FiercePharma and PharmExec, alongside Lilly’s own pages, has described a tiered structure in 2026 with monthly figures reported around:

• ~$299 for the lowest starting dose (the 2.5 mg strength)
• ~$399 for the next step (the 5 mg strength)
• ~$449 for higher doses (reported for the 7.5 mg through 15 mg strengths, with a timely refill)

Those figures reflect price cuts reported through 2026, when Lilly lowered the lower-dose vials and brought the higher doses down to the ~$449 tier. Dose strengths are noted here only as product identity for the pricing tiers; which strength is right for you is a prescriber-directed clinical decision, not something to select for price.

Importantly, the lower prices have come with conditions. Reporting describes the discounted higher-dose prices as available when the medicine is refilled within a set window — widely reported as about 45 days from the previous delivery. Miss that window and higher “maintenance” prices can apply instead; reporting has cited figures such as roughly $499 for the 7.5 mg strength and around $699 for the top doses without the timely refill. The mechanics matter as much as the headline number, because your effective monthly cost depends on staying inside that refill window.

Dose / route	Estimated monthly figure (verify current pricing)
Pharmacy pen, list price (no discount)	Roughly $1,000+ per month
LillyDirect self-pay, 2.5 mg (lowest dose)	Reported around $299
LillyDirect self-pay, 5 mg (next step)	Reported around $399
LillyDirect self-pay, 7.5–15 mg (timely refill)	Reported around $449
Higher doses without timely refill	Reported higher (e.g., ~$499–$699)

All figures are estimates from recent reporting and manufacturer pages and change frequently; confirm the current price for your dose and program at LillyDirect.

Zepbound cost with commercial insurance

If you have employer-sponsored or marketplace health insurance, your out-of-pocket cost depends entirely on your plan’s formulary coverage and benefit design.

Plans that cover Zepbound. A growing number of commercial plans have added Zepbound to their formularies, though it is typically classified as a specialty or non-preferred brand with higher cost-sharing. If your plan covers it, your costs might look like a preferred or specialty brand copay of roughly $50 to $150 per month, or a percentage-based coinsurance (often 25% to 33% on specialty medications) that can translate to several hundred dollars per month before any manufacturer discount is applied.

Plans that do not cover Zepbound. Many plans still exclude anti-obesity medications from their formularies entirely, and some large employers have added or dropped weight-loss drug coverage in recent plan years as costs are debated. If your plan does not cover Zepbound, you face the full cash price unless you use Lilly’s self-pay vials or another pathway. KFF (the Kaiser Family Foundation) has reported that coverage for weight-loss medications remains inconsistent across commercial plans, though it has generally been trending upward.

Prior authorization. Even when covered, Zepbound almost always requires prior authorization (PA). Your prescribing clinician must document that you meet the plan’s criteria — commonly a BMI of 30 or higher, or 27 or higher with at least one weight-related condition — and often that you have attempted lifestyle modification. The process can take days to weeks; your provider or pharmacist can help navigate it.

Step therapy requirements. Some plans require patients to try and fail a less expensive weight-loss medication before approving Zepbound. This is known as step therapy, and commonly named earlier-step options include phentermine, orlistat, or naltrexone-bupropion. Whether any alternative is appropriate is a clinical decision for your prescriber.

Zepbound cost without insurance / cash pay

When people ask how much Zepbound costs without insurance, they usually want one clean number, and there isn’t one. Paying full retail is the most expensive path: undiscounted pens have run roughly $1,000 or more per month, and a full-retail year can top $12,000. That is the ceiling, not the number most self-pay patients end up paying, because Lilly created the lower-cost routes described above.

For most cash-paying patients in 2026, the LillyDirect self-pay vials are the lowest-cost legitimate option — reported around $299 to $449 depending on the dose, with the lower maintenance price on higher doses often tied to refilling within the roughly 45-day window. Treat any specific figure as a snapshot rather than a fixed rate, and price your exact dose before committing.

A quick self-pay comparison before you commit can save real money:

• Confirm any insurance coverage first. A covered copay could beat every cash option, even for a specialty-tier drug.
• Price the LillyDirect self-pay vial for your specific dose against a pharmacy fill, and note the refill-timing condition so a maintenance price does not surprise you.
• Check the savings card if you have commercial insurance, to see whether it lowers your share further.
• Ask the pharmacist which route is cheapest for you on the day, since prices move.

Zepbound cost with Medicare and Medicaid

Coverage through government programs has specific limitations patients should understand.

Medicare Part D. By long-standing federal statute, Medicare Part D generally cannot cover a drug prescribed solely for weight loss, and as of early 2026 a broader federal rule to cover anti-obesity medications for weight loss has not been finalized. However, Medicare may cover a drug for a different, medically accepted indication. Because Zepbound is FDA-approved to treat moderate-to-severe OSA in adults with obesity, a number of Part D plans have added coverage for that specific indication. If you have OSA, ask your prescriber and plan whether Zepbound can be covered on that basis. Coverage details, prior authorization, and formulary placement vary by plan, so verify with your specific Part D or Medicare Advantage plan and confirm current CMS guidance.

Medicaid. Medicaid coverage for Zepbound varies by state. Some state Medicaid programs cover anti-obesity medications, while others exclude them; the OSA indication may also affect coverage in some states. Even where covered, prior authorization and step therapy are common. Contact your state Medicaid agency or managed-care plan to verify.

VA and military insurance. The Department of Veterans Affairs and TRICARE have their own policies on tirzepatide and other GLP-1 medications, with formulary placement and prior authorization requirements that change over time. VA coverage depends on clinical criteria and the individual facility. Check directly with your VA pharmacy or TRICARE plan.

Savings cards, self-pay, and the rules attached

Eli Lilly offers several programs designed to reduce the out-of-pocket cost of Zepbound for eligible patients. Terms change frequently, so confirm the latest details on Lilly’s official Zepbound and LillyDirect pages.

Zepbound Savings Card. Commercially insured patients whose plans cover Zepbound may be eligible for a manufacturer savings card that can reduce their copay to as little as roughly $25 per month, subject to a maximum benefit per fill and other terms. For commercially insured patients whose plan does not cover Zepbound, a separate non-covered version of the card has been reported at a higher fixed monthly figure. Critically, this program is only for people with commercial insurance. It is not available to patients enrolled in any government program — including Medicare, Medicare Part D, Medicare Advantage, Medicaid, TRICARE, or VA coverage. Do not rely on advertised copays without confirming your own eligibility against Lilly’s current terms.

How programs stack (or don’t). Savings cards and self-pay programs generally cannot be combined with insurance or government benefits. Self-pay vials are a cash route with no insurance applied — you generally cannot bill insurance against them. Patients with government insurance may still choose cash self-pay instead of billing a government plan. The practical rule: compare the cash price and the insured price, then use whichever is lower for your dose.

Patient assistance. Eli Lilly maintains assistance resources for eligible patients who meet income criteria, typically based on household income relative to the federal poverty level. Ask your prescriber or check Lilly’s official patient-support resources for current programs and how to apply. We do not list phone numbers here because contact details change; use Lilly’s official website to reach the correct program. It is worth re-verifying savings program availability and terms every couple of months, as pharmaceutical companies frequently update them.

Other ways to lower your Zepbound cost

Beyond manufacturer programs, several legitimate strategies can help reduce your out-of-pocket cost.

Pharmacy discount programs. GoodRx, RxSaver, and similar tools aggregate pricing across pharmacies and may offer coupons. Discounts on brand-name specialty medications like Zepbound are typically modest compared with generics, but they are worth checking — and sometimes a LillyDirect self-pay vial will be cheaper than a discounted pen at retail. Use a price-checker like GoodRx to compare on the day rather than assuming.

Switching between formulations. If your insurance covers Mounjaro (the diabetes brand of tirzepatide) but not Zepbound, and you have type 2 diabetes, your provider may be able to prescribe Mounjaro for blood-sugar management, which uses the same active ingredient and may have better coverage. This is a clinical decision your prescriber makes based on your diagnosis, not something to arrange around insurance alone; a Mounjaro price is not a substitute for a Zepbound prescription. For cost context, see how the same drug is priced as Mounjaro and Mounjaro costs without insurance.

Alternative GLP-1 medications. If Zepbound is not affordable, other medications may be covered by your insurance. Semaglutide (Wegovy) is the primary alternative for weight management, and some patients use liraglutide (Saxenda). Each has different pricing and coverage patterns. Our guide to semaglutide costs provides a detailed comparison, and you can see how these fit into overall tirzepatide pricing.

HSA and FSA. If you have a Health Savings Account or Flexible Spending Account, a prescribed weight-management medication is generally an eligible medical expense. Paying with pre-tax dollars effectively reduces your net cost by your marginal tax rate. Confirm eligibility rules with your plan administrator.

Putting the pieces together

Because the price is really a structure, the practical move is to price your specific dose across the routes before committing, and to plan for the ongoing cost since Zepbound is generally taken long term:

• Check any insurance coverage first — some plans cover Zepbound for approved uses, though many exclude weight-management drugs. If you have OSA, ask whether coverage is possible under that indication.
• Compare the LillyDirect self-pay price for your exact dose against a pharmacy fill, and note the refill-timing condition so a maintenance price does not surprise you.
• Look at the manufacturer savings card if you have commercial insurance.
• Map a few months ahead. Your dose may change during treatment, which can move you into a different self-pay tier, so leave a little room in your budget and re-check current numbers every couple of months.
• Ask the pharmacist which route is cheapest for you on the day, since prices move.

A warning about compounded and counterfeit tirzepatide

During the 2023–2024 tirzepatide shortage, compounding pharmacies were temporarily permitted to make copies of the drug, and many online sellers advertised low-cost “compounded tirzepatide.” That situation has changed. The FDA has declared the tirzepatide shortage resolved, and the grace periods that allowed large-scale compounding have ended, so mass compounding of tirzepatide has largely stopped. Compounded versions are not FDA-approved, are not tested for the same quality and potency as the brand product, and some products marketed online have been found to be counterfeit or improperly dosed.

Be especially wary of any website offering tirzepatide without a valid prescription, at prices that seem too good to be true, or from overseas sources. If a price looks dramatically below the ranges in this article — as some compounded or online offers do — treat it with caution and confirm exactly what you are buying with a licensed pharmacist or your clinician before you pay. Whether a compounded or off-brand product is appropriate is a clinical and safety question for your prescriber, not a cost decision to make alone. If cost is a barrier, use the legitimate pathways above rather than an unverified seller.

Important safety notes

Zepbound is a prescription medication that should be started and adjusted only under the direction of a licensed clinician. This article does not provide dosing instructions. A few safety points are worth knowing as you weigh the cost:

• Boxed warning. Tirzepatide carries an FDA boxed warning about the risk of thyroid C-cell tumors observed in animal studies. It should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Pancreatitis. Inflammation of the pancreas has been reported. Severe, persistent abdominal pain is a warning sign.
• Other effects. Gallbladder problems, dehydration from nausea or vomiting, and low blood sugar (especially when combined with certain diabetes medications) can occur.
• Pregnancy. Tirzepatide is not recommended during pregnancy, and weight-loss medications are generally stopped when pregnancy is planned or discovered. Discuss contraception and timing with your clinician.

Is Zepbound worth the cost?

The value equation extends beyond the monthly prescription cost. Consider these factors when evaluating whether the investment is worthwhile — ideally in a conversation with your clinician.

Health benefits. The NIH has documented that a 10% to 15% reduction in body weight produces meaningful improvements in blood pressure, blood sugar, cholesterol, sleep apnea, and joint pain. For people who reach those thresholds, that can reduce the burden of other conditions and, in some cases, the need for other medications.

Reduced future healthcare costs. Obesity is associated with significantly higher lifetime healthcare expenditures, according to CDC data. The cost of treating obesity-related conditions — including type 2 diabetes, cardiovascular disease, and certain cancers — can be substantial.

Quality of life. Patients in clinical trials reported improvements in physical functioning, mobility, energy, and well-being, which are difficult to quantify financially but meaningful.

Long-term commitment. Current evidence suggests that many patients regain weight after stopping GLP-1 medications; a study published in JAMA showed patients who discontinued tirzepatide regained a significant portion of lost weight over the following year. This means the financial commitment may be ongoing, which makes affordable, legitimate access even more important.

Frequently asked questions

What is the cost of Zepbound in 2026?

There is no single price. As of early 2026 the pens’ list price has run roughly $1,000 or more a month, while LillyDirect self-pay vials have been reported near $299, $399, and $449 depending on dose. With commercial coverage plus the savings card, copays can drop to as little as roughly $25/month. These are estimates that change — verify current pricing.

What is the cheapest way to get Zepbound?

It depends on your insurance. If your commercial plan covers Zepbound, combining that coverage with the manufacturer savings card can reduce your cost to as little as roughly $25 per month. Without coverage, Lilly’s self-pay vials through LillyDirect are typically the lowest-cost legitimate option and cost well below the pens’ list price — check current tier pricing. Lilly’s patient-assistance resources may help qualifying low-income patients. Avoid unverified compounded or no-prescription products.

Does the cost of Zepbound vary by dose?

For the injector pens, the list price has generally been the same across doses. Lilly’s self-pay vials, however, are tiered — lower doses cost less than higher doses. Because these prices have been adjusted more than once, confirm the current figures on LillyDirect rather than assuming a single flat price.

What is the 45-day refill rule about?

Reporting describes the lower self-pay prices on higher doses as tied to refilling within about 45 days of your previous delivery; miss that window and higher maintenance prices can apply. Confirm the current terms at LillyDirect.

Can I use a Zepbound savings card with Medicare or Medicaid?

Generally no. Manufacturer savings and self-pay card programs typically exclude people with government insurance such as Medicare, Medicaid, TRICARE, or VA benefits. Those patients may still use cash self-pay instead.

Can I combine self-pay vials with my insurance?

No. Self-pay is a cash route; you generally cannot apply insurance to it. Compare the cash and insured prices and use whichever is lower.

What if my insurance denies coverage for Zepbound?

You have several options. First, appeal the denial — your provider can submit additional clinical documentation supporting medical necessity, and many initial denials are overturned. Second, ask whether coverage is possible under the OSA indication if you have sleep apnea. Third, explore the savings card (if commercially insured) and LillyDirect self-pay vials. Fourth, discuss alternative covered GLP-1 medications with your provider.

Will Zepbound ever become generic?

Eli Lilly’s patents on tirzepatide extend for several more years, and generic versions are not expected in the near term. Competition could eventually lower prices, but for now there is no FDA-approved generic tirzepatide.

Can I buy Zepbound without a prescription?

No. Zepbound is prescription-only; a clinician must evaluate and prescribe it for its approved uses before any purchase route applies. Telehealth platforms, including Lilly’s own LillyDirect, can connect you with a clinician who may prescribe it after a medical evaluation — see our guide to getting Zepbound online.

Planning your path to affordable treatment

The Zepbound out-of-pocket cost is a significant consideration, but it should not be the sole factor in your treatment decision. Start by checking your insurance formulary, confirming whether the OSA indication applies to you, applying for the manufacturer savings card if you qualify, and comparing LillyDirect self-pay pricing with retail. If the branded medication remains out of reach, discuss other covered GLP-1 options with your provider — and avoid unverified online sellers. Weight management is a long-term health investment, and finding a sustainable, safe, and legitimate financial path is just as important as the clinical decision to start medication. For more on planning and lowering what you pay for care and medicines, see our healthcare costs guide.

Sources

• Eli Lilly — Zepbound.lilly.com and LillyDirect (list price, self-pay vial pricing by dose, program terms, coverage information)
• Eli Lilly — Zepbound Savings Card terms and eligibility (commercial insurance copay program; government-plan exclusions)
• FiercePharma and PharmExec — reporting on Lilly’s reductions to Zepbound single-dose vial self-pay prices and the associated refill conditions
• U.S. Food and Drug Administration (FDA) — Zepbound approvals (weight management; obstructive sleep apnea); tirzepatide shortage resolution; compounding guidance
• Centers for Medicare & Medicaid Services (CMS) — Medicare Part D coverage rules for anti-obesity medications
• KFF (Kaiser Family Foundation) — coverage of weight-loss drugs by commercial insurers and Medicaid
• GoodRx — retail and self-pay price-checking for tirzepatide products